Ultimately, the goal is to develop a shot that combines seasonal flu, COVID-19 and respiratory syncytial virus (RSV) protection with a single vaccine, said the biotech. It is also looking at including human metapneumovirus (hMPV), another common cause of upper respiratory tract infections.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,